^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    paclitaxel

    i
    Other names: BMY 45622, BMS-181339, NSC-125973, QW-8184, MBT-0206, NK-105, DHP-107
    Company:
    Generic mfg.
    Drug class:
    Tubulin inhibitor
    Related drugs:
    19h
    Dexamethasone drives macrophage repolarization linked to increased triple-negative breast cancer aggressiveness. (PubMed, Cell Death Dis)
    DEX treatment of an orthotopic mouse model of TNBC attenuated paclitaxel-mediated tumor growth inhibition, increased M2-like TAMs in primary tumors, and enhanced lung metastasis. Transcriptomic analysis of DEX-treated M1 macrophages revealed not only transcriptomic overlap with M2 macrophages, but also with human breast cancer TAM transcriptomic data, and further to a specific TAM signature associated with aggressive estrogen receptor-negative breast cancer. Our study illustrates a remarkable macrophage repolarization plasticity upon DEX exposure that can promote tumorigenesis, warranting care in prescribing high doses of GCs to breast cancer patients, especially to those considered for chemotherapy.
    Journal
    |
    ER (Estrogen receptor)
    |
    ER negative
    |
    paclitaxel • dexamethasone
    19h
    Formononetin protects against oxaliplatin-induced peripheral neurotoxicity via Nrf2/HO-1 antioxidant pathway without impairing anticancer efficacy. (PubMed, Neurotoxicology)
    Importantly, unlike the ROS scavenger N-acetylcysteine (NAC), which decreased the anticancer effectiveness of both oxaliplatin and paclitaxel, formononetin maintained their anticancer effects in colorectal cancer HT29 cells and cervical cancer SiHa cells. Taken together, formononetin holds potential as a neuroprotectant to prevent oxaliplatin-induced neurotoxicity without compromising anticancer efficacy.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • HMOX1 (Heme Oxygenase 1)
    |
    paclitaxel • oxaliplatin
    1d
    Role of LINC00332 in colorectal cancer progression and paclitaxel resistance. (PubMed, Cell Div)
    LINC00332 promotes PTX resistance and EMT in CRC via WNT and NOTCH pathways activation. It can also be suggested as a potential diagnostic marker in early-stage CRC patients. Targeting LINC00332 may enhance PTX response, warranting further studies for therapeutic application.
    Journal
    |
    CDH1 (Cadherin 1) • VIM (Vimentin) • CDH2 (Cadherin 2) • SNAI2 (Snail Family Transcriptional Repressor 2) • ZEB2 (Zinc Finger E-Box Binding Homeobox 2) • MMP3 (Matrix metallopeptidase 3)
    |
    paclitaxel
    1d
    Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=128, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Erbitux (cetuximab) • cisplatin • carboplatin • paclitaxel • docetaxel • fluorouracil topical
    1d
    NCI-2018-01836: Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer (clinicaltrials.gov)
    P2, N=48, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    carboplatin • sorafenib • paclitaxel
    2d
    eVOLVE-Lung02: A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. (clinicaltrials.gov)
    P3, N=1200, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK rearrangement • PD-L1 negative • ROS1 rearrangement
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • volrustomig (MEDI5752)
    2d
    DESTINY-Breast08: A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=138, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2025 --> Jun 2026
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 expression • HER-2 underexpression • PGR positive
    |
    Imfinzi (durvalumab) • paclitaxel • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • fulvestrant • Truqap (capivasertib) • anastrozole
    2d
    KEYMAKER-U06 substudy 06A: A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A) (clinicaltrials.gov)
    P1/2, N=90, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    Keytruda (pembrolizumab) • paclitaxel • Lenvima (lenvatinib) • irinotecan • MK-4830 • favezelimab/pembrolizumab (MK-4280A)
    2d
    Paclitaxel Therapeutic Drug Monitoring in Cancer Patients (clinicaltrials.gov)
    P=N/A, N=20, Recruiting, Wake Forest University Health Sciences | Trial completion date: Jan 2026 --> Jul 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    paclitaxel
    2d
    HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer (clinicaltrials.gov)
    P3, N=468, Recruiting, Hansoh BioMedical R&D Company | Not yet recruiting --> Recruiting
    Enrollment open • Platinum resistant
    |
    paclitaxel • doxorubicin hydrochloride • topotecan • mocertatug rezetecan (GSK5733584)
    2d
    A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer (clinicaltrials.gov)
    P1, N=27, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | N=40 --> 27 | Trial completion date: Aug 2026 --> Dec 2025 | Trial primary completion date: Aug 2026 --> Dec 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel
    3d
    JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma. (clinicaltrials.gov)
    P3, N=560, Not yet recruiting, Shanghai Junshi Bioscience Co., Ltd.
    New P3 trial
    |
    paclitaxel • docetaxel • irinotecan